Focused On-demand Library for Phosphatidylserine lipase ABHD16A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Alpha/beta hydrolase domain-containing protein 16A; HLA-B-associated transcript 5; Monoacylglycerol lipase ABHD16A; Protein G5

Alternative UPACC:

O95870; A2BEY3; B7Z4R6; Q5SRR1; Q5SRR2; Q8WYH0; Q9NW33


Phosphatidylserine lipase ABHD16A, also known as Alpha/beta hydrolase domain-containing protein 16A, HLA-B-associated transcript 5, Monoacylglycerol lipase ABHD16A, and Protein G5, plays a crucial role in lipid metabolism. It mediates the hydrolysis of phosphatidylserine to generate lysophosphatidylserine, a signaling lipid involved in immunological and neurological processes. Additionally, ABHD16A exhibits monoacylglycerol lipase activity, with a preference for specific lipid substrates.

Therapeutic significance:

Given its involvement in neurodegenerative disorders like Spastic paraplegia 86, autosomal recessive, characterized by progressive weakness and spasticity of the lower limbs, understanding the role of Phosphatidylserine lipase ABHD16A could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.